Literature DB >> 30374811

Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma.

Dimitrios E Magouliotis1,2, Vasiliki S Tasiopoulou3, Kalliopi Athanassiadi4.   

Abstract

OBJECTIVE: We reviewed the available literature on patients with MPM undergoing either extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D).
METHODS: Original research studies that evaluated long-term outcomes of P/D versus EPP were identified, from January 1990 to July 2018. The 30 and 90 days mortality, along with the 1-, 2-, 3-, 5-year survival, the median overall survival and the complications were calculated according to both a fixed and a random effect model. The Q statistics and I2 statistic were used to test for heterogeneity among the studies.
RESULTS: Fifteen studies were included, incorporating a total of 1672 patients treated with EPP and 2236 treated with P/D. The 30-day mortality was significantly higher in the EPP group [OR 3.24 (95% CI 1.70, 6.20); p < 0.001]. The median overall survival was significantly increased in the P/D group [WMD - 4.20 (- 5.66, - 2.74); p < 0.001]. No significant differences were found regarding the 90-day mortality and the 1-, 2-, 3-, 5-year survival between the EPP and P/D groups. The incidence of postoperative atrial fibrillation, hemorrhage, empyema, bronchopleural fistula and air leak was significantly increased in the EPP group (p < 0.05).
CONCLUSIONS: The present meta-analysis indicates that P/D is associated with enhanced outcomes regarding 30-day mortality, median overall survival, and complications. The P/D approach, should, therefore be preferred when technically feasible. However, the decision regarding the procedure of choice should be made on the basis of the disease status and the surgeon's experience. Well-designed, randomized studies, comparing EPP to P/D, are necessary to further assess their clinical outcomes.

Entities:  

Keywords:  Decortication; Extrapleural pneumonectomy; Malignant pleural mesothelioma; Pleurectomy

Mesh:

Year:  2018        PMID: 30374811     DOI: 10.1007/s11748-018-1027-6

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  24 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

2.  Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.

Authors:  David J Sugarbaker; Andrea S Wolf; Lucian R Chirieac; John J Godleski; Tamara R Tilleman; Michael T Jaklitsch; Raphael Bueno; William G Richards
Journal:  Eur J Cardiothorac Surg       Date:  2011-02-09       Impact factor: 4.191

3.  Malignant pleural mesothelioma: surgical management in 285 patients.

Authors:  Paul H Schipper; Francis C Nichols; Kristine M Thomse; Claude Deschamps; Stephen D Cassivi; Mark S Allen; Peter C Pairolero
Journal:  Ann Thorac Surg       Date:  2008-01       Impact factor: 4.330

4.  The management of malignant pleural mesothelioma; single centre experience in 10 years.

Authors:  Tarek Aziz; Ali Jilaihawi; Dhruva Prakash
Journal:  Eur J Cardiothorac Surg       Date:  2002-08       Impact factor: 4.191

5.  Diagnostic and therapeutic strategy in malignant pleural mesothelioma.

Authors:  D Branscheid; S Krysa; E Bauer; H Bülzebruck; J Schirren
Journal:  Eur J Cardiothorac Surg       Date:  1991       Impact factor: 4.191

6.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

7.  Three decades of experience in the surgical multi-modality management of pleural mesothelioma.

Authors:  Heyman Luckraz; Mesbah Rahman; Nishith Patel; Adam Szafranek; Allen R Gibbs; Eric G Butchart
Journal:  Eur J Cardiothorac Surg       Date:  2009-08-29       Impact factor: 4.191

8.  Treatment of mesothelioma in Bloemfontein, South Africa.

Authors:  W J de Vries; M A Long
Journal:  Eur J Cardiothorac Surg       Date:  2003-09       Impact factor: 4.191

9.  Radical surgery for malignant pleural mesothelioma: results and prognosis.

Authors:  Morihito Okada; Takeshi Mimura; Chiho Ohbayashi; Toshiko Sakuma; Toshinori Soejima; Noriaki Tsubota
Journal:  Interact Cardiovasc Thorac Surg       Date:  2007-11-29

10.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

View more
  3 in total

1.  Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR).

Authors:  Dimitrios E Magouliotis; Prokopis-Andreas Zotos; Arian Arjomandi Rad; Despoina Koukousaki; Vasiliki Vasilaki; Ioustini Portesi; Kyriakos Spiliopoulos; Thanos Athanasiou
Journal:  Updates Surg       Date:  2022-09-03

2.  The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis.

Authors:  Olivia Lauk; Karina Bruestle; Thomas Neuer; Bianca Battilana; Thi Dan Linh Nguyen; Thomas Frauenfelder; Rolf Stahel; Walter Weder; Alessandra Curioni-Fontecedro; Isabelle Opitz
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

Review 3.  Systematic Review and Meta-Analysis of Pleurectomy/Decortication versus Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma.

Authors:  Federica Danuzzo; Sebastiano Maiorca; Gianluca Bonitta; Mario Nosotti
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.